Status:
RECRUITING
Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction
Lead Sponsor:
Shanghai Tong Ren Hospital
Conditions:
Early PCSK9 Inhibitor on Ventricular Remodling
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
This is a prospect, multi-center, random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after primary percutaneous...
Eligibility Criteria
Inclusion
- Subject must be at least 18 years of age and less than 80 years old
- Patients should have undergone successful percutaneous coronary intervention with drug-eluting stent for AMI and LAD should be the only culprit vessel.
- Subject understand the study requirements and the treatment procedures and provided informed consent before the procedure
Exclusion
- Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
- Known hypersensitivity or contraindication to study medications
- Plan to receive revascularization in next six month.
- Have received revascularization before.
- Subjects with life expectation less than one year.
- Subjects with active malignant tumor
- subjects with severe liver or renal dysfunction（ALT \>5倍ULA，eGFR\<15ml/min/1.73mm2）
- Other conditions which the investigators think not applicable to the study.
Key Trial Info
Start Date :
April 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04731155
Start Date
April 12 2021
End Date
October 1 2025
Last Update
May 21 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongren Hospital, Shanghai
Shanghai, Shanghai Municipality, China
2
Shanghai tenth people's hospital
Shanghai, China